Metastatic Non-small Cell Lung Cancer Clinical Trials

110 clinical trials for Metastatic Non-small Cell Lung Cancer across international registries, including 27 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) — RECRUITING · PHASE2
• A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer — RECRUITING · PHASE1
• Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers — RECRUITING · PHASE2
• A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion. — RECRUITING · PHASE3
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 — RECRUITING · PHASE2
• A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing — RECRUITING · PHASE1
• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations — RECRUITING · PHASE3
• A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — RECRUITING · PHASE2
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — RECRUITING · PHASE3
• Safety and Efficacy of OBX-115 in Advanced Solid Tumors — RECRUITING · PHASE1
• Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer — RECRUITING · PHASE1
• Pilot Study of the Contribution of Fractional Exhaled Nitric Oxide as a Prognostic Marker of Response to Anti-PD-L1 Immunotherapy in Non-small Cell Lung Cancer — RECRUITING
• Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer — RECRUITING · PHASE2
• LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC — RECRUITING · PHASE3
• MOv19-BBz CAR T Cells in FRa+ Cancers — RECRUITING · PHASE1
• Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) — RECRUITING · PHASE2
• A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer progressing after first-line chemo-immunotherapy (Combi-TED) — RECRUITING · PHASE2
• A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer — RECRUITING · PHASE3
• Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer — RECRUITING · PHASE1
• A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer — RECRUITING · PHASE2
• Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC — RECRUITING · PHASE3
• Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade — RECRUITING · PHASE2
• Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer — RECRUITING
• Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients — RECRUITING
• Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer — RECRUITING · PHASE3
• The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients — RECRUITING · NA
• Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients — RECRUITING
• Effects of SmofKabiven® E, a nutrition solution given into the vein, in lung cancer patients — TERMINATED · PHASE4
• Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of DS-3939a in Participants With Solid Tumors — NOT_YET_RECRUITING · PHASE1
• A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. — ACTIVE_NOT_RECRUITING · PHASE3
• Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) — TERMINATED · PHASE3
• Plasma-Adapted First-Line Pembro In NSCLC — ACTIVE_NOT_RECRUITING · PHASE2
• Dupilumab_Metastatic NSCLC — COMPLETED · PHASE1
• Body Composition and Blood-Based Prognostic Markers in Immunotherapy-Treated Metastatic Non-Small Cell Lung Cancer — COMPLETED
• A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater than or Equal to 50% (TroFuse-007) — TERMINATED · PHASE3
• A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non–Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations — TERMINATED · PHASE3
• Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) — COMPLETED · PHASE2
• Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations — ACTIVE_NOT_RECRUITING · PHASE3
• A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR) — NOT_YET_RECRUITING · PHASE2
• A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC — OTHER · PHASE1
• A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3) — TERMINATED · PHASE3
• A Phase III, Two- Arm, Parallel, Randomized, Multi-Center, Open‑Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC) (eVOLVE-Lung02) — COMPLETED · PHASE3
• Investigation-specific Appendix 2to Master Protocol PLATFORMPANSC2001 (KALEIDOSCOPE) A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Cetrelimab Combination Therapy in Metastatic Non-small Cell Lung Cancer - PolyDamas — TERMINATED · PHASE2
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations — ACTIVE_NOT_RECRUITING · PHASE1
• An Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of EDB-102 in Patients With EGFR L858R-Mutant, Third-Generation TKI-Resistant Advanced Non-Small Cell Lung Cancer With Liver Metastases — NOT_YET_RECRUITING · PHASE1
• CISH Inactivated TILs in the Treatment of NSCLC — WITHDRAWN · PHASE1

Refine this search